CERo Therapeutics Holdings ( (CERO) ) has issued an update.
CERo Therapeutics Holdings, Inc. has secured $1.25 million through a private placement, selling Series C preferred stock and warrants to accredited investors. These funds are aimed at advancing the company’s lead immunotherapy product, CER-1236, and addressing FDA concerns. In leadership shifts, Vice Chairman Chris Ehrlich steps up as interim CEO following Brian Atwood’s resignation, with ongoing management changes and cost reduction strategies to streamline operations and focus on bringing CER-1236 to clinical trials for cancer treatment.
See more data about CERO stock on TipRanks’ Stock Analysis page.
